Dr Jennifer May's Outputs (37)

Bone marrow and myeloma cellular communication protects from genotoxicity in a drug-specific manner (2015)
Journal Article

Multiple myeloma (MM) is an incurable haematological malignancy with most patients eventually developing ad- vanced, relapsing disease and drug resistance (1,2). This may result from protection by BM mesenchymal cells (BM— MSC) interacting with MM ce... Read More about Bone marrow and myeloma cellular communication protects from genotoxicity in a drug-specific manner.

Chemotherapy-induced cytotoxicity and genotoxicity to the bone marrow microenvironment (2013)
Journal Article

The bone marrow (BM) microenvironment is largely com- prised of mesenchymal stromal cells (MSCs) and is vital in supporting haematopoiesis. Limited studies have indicated that the BM microenvironment is damaged by chemotherapy; however the extent and... Read More about Chemotherapy-induced cytotoxicity and genotoxicity to the bone marrow microenvironment.

Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy (2013)
Journal Article

Cytosine arabinoside (ara-C) is a key chemotherapy drug used to treat acute myeloid leukaemia (AML), however, ap- proximately 30% of patients do not respond to this therapy.
92
An evaluative assay to determine resistance/sensitivity to ara- C prior... Read More about Effects of bone marrow stromal cells on sensitivity of leukaemic cells to chemotherapy.

Use of whole blood for analysis of disease-associated biomarkers (2013)
Journal Article

Analyses for diagnosis and monitoring of pathological conditions often rely on blood samples, partly due to relative ease of collection. However, many interfering substances largely preclude the use of whole blood itself, necessitating separation of... Read More about Use of whole blood for analysis of disease-associated biomarkers.

Multiple myeloma: The bone marrow microenvironment and its relation to treatment (2013)
Journal Article

Multiple myeloma is the most common haematological malignancy yet currently it remains incurable. For decades the mainstay in therapy has been non-targeted approaches including genotoxic agents and immunosuppressants. With myeloma predominantly affec... Read More about Multiple myeloma: The bone marrow microenvironment and its relation to treatment.

Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells (2012)
Journal Article

There is an increasing need for development of physiologically relevant in-vitro models for testing toxicity, however determining toxic effects of agents which undergo extensive hepatic metabolism can be particularly challenging. If a source of such... Read More about Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells.

Development of a novel, physiologically relevant cytotoxicity model: application to the study of chemotherapeutic damage to mesenchymal stromal cells (2012)
Journal Article

Chemotherapy-induced damage to mesenchymal stem cells: An in vitro model (2011)
Presentation / Conference Contribution

Chemotherapy-induced damage to mesenchymal stem cells: An in vitro model (2011)
Journal Article

Development of an in vitro model to investigate the effect of chemotherapeutic treatment on mesenchymal stromal cells (2010)
Thesis

An in vitro model of chemotherapeutic damage to mesenchymal stem cells (2010)
Presentation / Conference Contribution

Chemotherapeutic damage to mesenchymal stem cells (2010)
Presentation / Conference Contribution

Modelling chemotherapeutic damage to mesenchymal stem cells (2010)
Journal Article

Mesenchymal stem cell response to chemotherapeutic damage (2009)
Presentation / Conference Contribution

Mesenchymal stem/stromal cell (MSC) response to chemotherapeutic damage (2009)
Presentation / Conference Contribution

Toxicity testing: The search for an in vitro alternative to animal testing (2009)
Journal Article

Prior to introduction to the clinic, pharmaceuticals must undergo rigorous toxicity testing to ensure their safety. Traditionally, this has been achieved using in vivo animal models. However, besides ethical reasons, there is a continual drive to red... Read More about Toxicity testing: The search for an in vitro alternative to animal testing.

Abstracts of the 33rd Annual Meeting of the United Kingdom Environmental Mutagen Society, July 12-14, 2010, Derby, United Kingdom.
Presentation / Conference Contribution